XNYS · PHARMACEUTICAL PREPARATIONS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Johnson & Johnson (JNJ) had 1 Form 144 pre-sale notice filed on 2026-06-11. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 6/11/2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | OPTION_EXERCISE | -10,000 | — | — |
| 6/11/2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | SELL | -10,000 | $241 | $2,411,500 |
| 6/11/2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | OPTION_EXERCISE | 10,000 | $116 | $1,156,700 |
| 6/9/2026 | HEWSON MARILLYN A | — | GRANT | 214.79 | $233 | $50,000 |
| 6/9/2026 | Pinto Daniel E | — | GRANT | 134.24 | $233 | $31,250 |
| 6/9/2026 | Woods Eugene A. | — | GRANT | 161.09 | $233 | $37,500 |
| 5/1/2026 | REED JOHN C | EVP, Innovative Medicine, R&D | OPTION_EXERCISE | 25,255 | — | — |
| 5/1/2026 | REED JOHN C | EVP, Innovative Medicine, R&D | TAX_WITHHOLD | -11,002 | $230 | $2,528,810 |
| 5/1/2026 | REED JOHN C | EVP, Innovative Medicine, R&D | OPTION_EXERCISE | -25,255 | — | — |
| 4/23/2026 | Woods Eugene A. | — | GRANT | 975 | — | — |
| 4/23/2026 | West Nadja | — | GRANT | 975 | — | — |
| 4/23/2026 | WEINBERGER MARK A | — | GRANT | 975 | — | — |
| 4/23/2026 | Pinto Daniel E | — | GRANT | 1,712 | — | — |
| 4/23/2026 | MORIKIS JOHN G | — | GRANT | 1,540 | — | — |
| 4/23/2026 | McClellan Mark B. | — | GRANT | 975 | — | — |
| 4/23/2026 | Joly Hubert | — | GRANT | 975 | — | — |
| 4/23/2026 | Johnson Paula A | — | GRANT | 975 | — | — |
| 4/23/2026 | HEWSON MARILLYN A | — | GRANT | 975 | — | — |
| 4/23/2026 | Doudna Jennifer A | — | GRANT | 975 | — | — |
| 3/10/2026 | HEWSON MARILLYN A | — | GRANT | 206.49 | $242 | $50,000 |
| Date | Filer | Relationship | Est. shares | Filing |
|---|---|---|---|---|
| 6/11/2026 | Wengel Kathryn E | — | 10,000 | SEC |